Clinical Trial Update: Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated trametinib (GSK1120212) plus gemcitabine versus placebo plus gemcitabine in metastatic pancreatic cancer. The study has completed a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• MEKINIST (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-09-26